Matches in SemOpenAlex for { <https://semopenalex.org/work/W2575804911> ?p ?o ?g. }
- W2575804911 endingPage "1011" @default.
- W2575804911 startingPage "1001" @default.
- W2575804911 abstract "This phase II study examined whether the addition of simvastatin to afatinib provides a clinical benefit compared with afatinib monotherapy in previously treated patients with nonadenocarcinomatous non-small cell lung cancer (NA-NSCLC).Patients with advanced NA-NSCLC who progressed after one or two chemotherapy regimens were randomly assigned to a simvastatin (40 mg/day) plus afatinib (40 mg/day) (AS) arm or to an afatinib (A) arm. The primary endpoint was response rate (RR).Sixty-eight patients were enrolled (36 in the AS arm and 32 in the A arm). The RR was 5.7% (95% confidence interval [CI], 0.7 to 19.2) for AS and 9.4% (95% CI, 2.0 to 25.0) for A (p=0.440). In arms AS and A, the median progression-free survival (PFS) was 1.0 versus 3.6 months (p=0.240) and the overall survival was 10.0 months versus 7.0 months (p=0.930), respectively. Skin rash, stomatitis, and diarrhea were the most common adverse events in both arms. More grade 3 or 4 diarrhea was observed in arm A (18.8% vs. 5.6% in arm AS). In all patients, the median PFS for treatment including afatinib was not correlated with the status of epidermal growth factor receptor (EGFR) mutation (p=0.122), EGFR fluorescence in situ hybridization (p=0.944), or EGFR immunohistochemistry (p=0.976). However, skin rash severity was significantly related to the risk of progression for afatinib (hazard ratio for skin rash grade ≥ 2 vs. grade < 2, 0.44; 95% CI, 0.25 to 0.78; p=0.005).There were no significant differences in the efficacy between AS and A arms in patients with NA-NSCLC." @default.
- W2575804911 created "2017-01-26" @default.
- W2575804911 creator A5004340711 @default.
- W2575804911 creator A5005962138 @default.
- W2575804911 creator A5019571637 @default.
- W2575804911 creator A5023055777 @default.
- W2575804911 creator A5025388629 @default.
- W2575804911 creator A5026667487 @default.
- W2575804911 creator A5055974749 @default.
- W2575804911 creator A5079274190 @default.
- W2575804911 creator A5082220016 @default.
- W2575804911 date "2017-10-15" @default.
- W2575804911 modified "2023-10-12" @default.
- W2575804911 title "Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer" @default.
- W2575804911 cites W1548555206 @default.
- W2575804911 cites W1978658336 @default.
- W2575804911 cites W1983159571 @default.
- W2575804911 cites W1988442083 @default.
- W2575804911 cites W2010734528 @default.
- W2575804911 cites W2014064711 @default.
- W2575804911 cites W2019607817 @default.
- W2575804911 cites W2043696829 @default.
- W2575804911 cites W2057238214 @default.
- W2575804911 cites W2079430799 @default.
- W2575804911 cites W2088093215 @default.
- W2575804911 cites W2097254028 @default.
- W2575804911 cites W2097781997 @default.
- W2575804911 cites W2111662961 @default.
- W2575804911 cites W2113341349 @default.
- W2575804911 cites W2114293271 @default.
- W2575804911 cites W2122438688 @default.
- W2575804911 cites W2129360604 @default.
- W2575804911 cites W2132157071 @default.
- W2575804911 cites W2137043950 @default.
- W2575804911 cites W2138297714 @default.
- W2575804911 cites W2138604360 @default.
- W2575804911 cites W2146570456 @default.
- W2575804911 cites W2155421604 @default.
- W2575804911 cites W2158043872 @default.
- W2575804911 cites W2160982674 @default.
- W2575804911 cites W2161821474 @default.
- W2575804911 cites W2171138151 @default.
- W2575804911 cites W2171139285 @default.
- W2575804911 cites W2330761849 @default.
- W2575804911 doi "https://doi.org/10.4143/crt.2016.546" @default.
- W2575804911 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5654166" @default.
- W2575804911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28111428" @default.
- W2575804911 hasPublicationYear "2017" @default.
- W2575804911 type Work @default.
- W2575804911 sameAs 2575804911 @default.
- W2575804911 citedByCount "37" @default.
- W2575804911 countsByYear W25758049112018 @default.
- W2575804911 countsByYear W25758049112019 @default.
- W2575804911 countsByYear W25758049112020 @default.
- W2575804911 countsByYear W25758049112021 @default.
- W2575804911 countsByYear W25758049112022 @default.
- W2575804911 countsByYear W25758049112023 @default.
- W2575804911 crossrefType "journal-article" @default.
- W2575804911 hasAuthorship W2575804911A5004340711 @default.
- W2575804911 hasAuthorship W2575804911A5005962138 @default.
- W2575804911 hasAuthorship W2575804911A5019571637 @default.
- W2575804911 hasAuthorship W2575804911A5023055777 @default.
- W2575804911 hasAuthorship W2575804911A5025388629 @default.
- W2575804911 hasAuthorship W2575804911A5026667487 @default.
- W2575804911 hasAuthorship W2575804911A5055974749 @default.
- W2575804911 hasAuthorship W2575804911A5079274190 @default.
- W2575804911 hasAuthorship W2575804911A5082220016 @default.
- W2575804911 hasBestOaLocation W25758049111 @default.
- W2575804911 hasConcept C121608353 @default.
- W2575804911 hasConcept C126322002 @default.
- W2575804911 hasConcept C141071460 @default.
- W2575804911 hasConcept C143998085 @default.
- W2575804911 hasConcept C168563851 @default.
- W2575804911 hasConcept C197934379 @default.
- W2575804911 hasConcept C203092338 @default.
- W2575804911 hasConcept C207103383 @default.
- W2575804911 hasConcept C2776256026 @default.
- W2575804911 hasConcept C2776694085 @default.
- W2575804911 hasConcept C2778570526 @default.
- W2575804911 hasConcept C2779438470 @default.
- W2575804911 hasConcept C2780580887 @default.
- W2575804911 hasConcept C2780586478 @default.
- W2575804911 hasConcept C31760486 @default.
- W2575804911 hasConcept C44249647 @default.
- W2575804911 hasConcept C71924100 @default.
- W2575804911 hasConcept C90924648 @default.
- W2575804911 hasConceptScore W2575804911C121608353 @default.
- W2575804911 hasConceptScore W2575804911C126322002 @default.
- W2575804911 hasConceptScore W2575804911C141071460 @default.
- W2575804911 hasConceptScore W2575804911C143998085 @default.
- W2575804911 hasConceptScore W2575804911C168563851 @default.
- W2575804911 hasConceptScore W2575804911C197934379 @default.
- W2575804911 hasConceptScore W2575804911C203092338 @default.
- W2575804911 hasConceptScore W2575804911C207103383 @default.
- W2575804911 hasConceptScore W2575804911C2776256026 @default.
- W2575804911 hasConceptScore W2575804911C2776694085 @default.
- W2575804911 hasConceptScore W2575804911C2778570526 @default.
- W2575804911 hasConceptScore W2575804911C2779438470 @default.